Part:BBa_K3506095
Constitutive double promoter module
Constitutive double promoter system is composed of GAPDH promoter (BBa_K3506020) and U6 promoter (BBa_K3506021).
It is generally accepted that GAPDH promoter is considered to be a strong constitutive promoter which is recognized by RNA polymerase II.
U6 promoter is used to drive the expression of guide RNA (gRNA) in lineage tracing for eukaryotic systems. We put GAPDH promoter in the upstream of U6 promoter. The system can read the information of gRNAs out of the transcriptomic information by polyA tail.
Biology and Usage
GAPDH promoter is considered to be a strong constitutive promoter which is recognized by RNA polymerase II.
U6 promoter promoter is used to drive the transcription of small non-coding RNAs [1] and it is recognized by RNA polymerase III.
In our project, we use U6 promoter to transcribe functional gRNA without polyA tail [2]. We use GAPDH promoter to transcribe gRNA and add a polyA tail. Therefore, gRNA can not only work with CRISPR/Cas9 system, but also be reverse transcribed by oligodT. It enables us to read the lineage information in gRNA together with the transcriptomic information when single cell RNA sequencing.
Sequence and Feature
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 436
Design and Properties
We tested the constitutive double promoter module. This test is divided into two steps.
First step: to test whether GAPDH promoter will affect the production and the function of gRNA. We put gRNA targeting ADE2 gene downstream of U6 promoter in both the experimental group and control group. Put GAPDH promoter upstream of U6 promoter only in the experimental group. Results showed that both of the two groups turned red, thus GAPDH promoter won’t affect the production and the function of gRNA.
Second step: to test that whether gRNA can be reverse transcribed using oligo dT as the primer. For both the experimental group and the control group, we extracted total mRNA of these purified red colonies by TRIzol. Then the mRNA was reverse transcribed using oligo dT as the primer. To test whether gRNA can be transcribed, we performed PCR on reverse transcription products by two specific primers. Agarose gel electrophoresis were performed on the PCR product. There came out a correct band (208bp). Then we sequenced the products and get the anticipated results.
Experimental approach
1.Construct recombinant plasmid. Get GAPDH promoter from the genome of Cryptococcus neoformans. Insert it upstream of U6 promoter on PRH003 plasmid.
2.Transform the product (2.5μL) into DH5α competent cells（50μL）, grow cells on LB-amphenicol medium. Incubate at 37°C overnight. Monoclones are selected by colony PCR. Expanding culture colonies at 37℃ 200rpm, then extracting plasmids and sequencing.
3.Use Kpn1 enzyme to linearise the plasmids and transform them into Cryptococcus neoformans by electroporation.
4.The C. neoformans is spread on YNBA selection medium, and the transformants grow after being cultured in an incubator kept at 30℃ for 4 days. Then the culture is transferred to a refrigerator at 4℃.
5.Red colonies are selected and inoculated into YPD medium, then placed in an incubator kept at 30℃ for 4 days. Finally it is kept at 4℃ refrigerator.
6.For both the experimental group and the control group, we first extract the total mRNA of these red colonies by TRIzol. Then the mRNA is reverse transcribed using oligodT as the primer.
7.To test whether gRNA can be reverse transcribed, we perform PCR on the reverse transcription products by two specfic primers. Then sequencing the PCR products to further prove the success of our design.
References
[1]Duttke S. H. (2014). RNA polymerase III accurately initiates transcription from RNA polymerase II promoters in vitro. The Journal of biological chemistry, 289(29), 20396–20404.
[2]Gao, Z., Herrera-Carrillo, E., & Berkhout, B. (2018). RNA Polymerase II Activity of Type 3 Pol III Promoters. Molecular therapy. Nucleic acids, 12, 135–145.
| None |